Variant III of the epidermal growth factor receptor (EGFRvIII), the most common variant of EGFR first identified in human GBM, is also present in many other tumor types, but is not found in healthy tissues (Li and Wong, 2008), which makes EGFRvIII a suitable target for CAR-T cell therapy. Here, EGFR is linked to neoplasm.